Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $3.00 billion. The enterprise value is $2.03 billion.
| Market Cap | 3.00B |
| Enterprise Value | 2.03B |
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 160.29 million shares outstanding. The number of shares has increased by 7.68% in one year.
| Current Share Class | 160.29M |
| Shares Outstanding | 160.29M |
| Shares Change (YoY) | +7.68% |
| Shares Change (QoQ) | +2.54% |
| Owned by Insiders (%) | 2.96% |
| Owned by Institutions (%) | 97.64% |
| Float | 155.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 140.48 |
| Forward PS | 18.91 |
| PB Ratio | 3.24 |
| P/TBV Ratio | 3.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 95.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.21, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.21 |
| Quick Ratio | 5.62 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.94% and return on invested capital (ROIC) is -174.56%.
| Return on Equity (ROE) | -33.94% |
| Return on Assets (ROA) | -28.69% |
| Return on Invested Capital (ROIC) | -174.56% |
| Return on Capital Employed (ROCE) | -45.70% |
| Weighted Average Cost of Capital (WACC) | 10.08% |
| Revenue Per Employee | $42,174 |
| Profits Per Employee | -$620,164 |
| Employee Count | 507 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $102,000 in taxes.
| Income Tax | 102,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.96% in the last 52 weeks. The beta is 1.08, so DNLI's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +6.96% |
| 50-Day Moving Average | 19.77 |
| 200-Day Moving Average | 21.23 |
| Relative Strength Index (RSI) | 43.53 |
| Average Volume (20 Days) | 1,602,576 |
Short Selling Information
The latest short interest is 14.69 million, so 9.17% of the outstanding shares have been sold short.
| Short Interest | 14.69M |
| Short Previous Month | 15.48M |
| Short % of Shares Out | 9.17% |
| Short % of Float | 9.45% |
| Short Ratio (days to cover) | 8.39 |
Income Statement
In the last 12 months, DNLI had revenue of $21.38 million and -$314.42 million in losses. Loss per share was -$1.70.
| Revenue | 21.38M |
| Gross Profit | -392.20M |
| Operating Income | -530.51M |
| Pretax Income | -314.32M |
| Net Income | -314.42M |
| EBITDA | -514.00M |
| EBIT | -530.51M |
| Loss Per Share | -$1.70 |
Balance Sheet
The company has $1.01 billion in cash and investments and $35.24 million in debt, with a net cash position of $972.33 million or $6.07 per share.
| Cash & Investments | 1.01B |
| Total Debt | 35.24M |
| Net Cash | 972.33M |
| Net Cash Per Share | $6.07 |
| Equity (Book Value) | 926.39M |
| Book Value Per Share | 5.78 |
| Working Capital | 496.45M |
Cash Flow
In the last 12 months, operating cash flow was -$444.19 million and capital expenditures -$5.81 million, giving a free cash flow of -$449.99 million.
| Operating Cash Flow | -444.19M |
| Capital Expenditures | -5.81M |
| Depreciation & Amortization | 16.52M |
| Net Borrowing | -76,000 |
| Free Cash Flow | -449.99M |
| FCF Per Share | -$2.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,481.12% |
| Pretax Margin | -1,470.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.68% |
| Shareholder Yield | -7.68% |
| Earnings Yield | -9.10% |
| FCF Yield | -14.98% |
Analyst Forecast
The average price target for DNLI is $36.19, which is 93.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.19 |
| Price Target Difference | 93.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNLI has an Altman Z-Score of 2.35. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.35 |
| Piotroski F-Score | n/a |